Alzheimer’s Disease
January 6, 2023
[ad_1] The drug Leqembi may slightly slow cognitive decline in the early stages of the disease, but it comes with some safety risks. However, data suggests it holds more promise than the small number of other treatments available. [ad_2] Source link
December 29, 2022
[ad_1] The report said the FDA’s approval process for Aduhelm was “riddled with irregularities” and criticized Biogen for setting an “unjustifiably high price.” [ad_2] Source link
December 2, 2022
[ad_1] Preliminary results give hope that gene therapy can protect people with a version of the brain disease caused by a specific gene variant. [ad_2] Source link
